Transcode Therapeutics, Inc.

# Transcode Therapeutics, Inc. (RNAZ)

Based in Boston, Massachusetts, this biopharmaceutical company develops RNA-based therapeutics and diagnostics targeting cancer. The company's clinical-stage lead candidate, TTX-MC138, is designed to modulate microRNA-10b, which regulates metastatic cell survival across multiple cancer types including breast, pancreatic, ovarian, and colon cancers, as well as glioblastomas. The company pursues a pipeline of preclinical programs utilizing various modalities, including an siRNA-based programmed death-ligand 1 modulator (TTX-siPDL1), an RNA agonist targeting innate immune activation (TTX-RIGA), a CRISPR/Cas9 platform for tumor-suppressor gene modification (TTX-CRISPR), and an mRNA cancer vaccine platform (TTX-mRNA).

The company maintains a strategic collaboration with The University of Texas M.D. Anderson Cancer Center to support its research and development efforts. Transcode operates with a minimal employee base of seven full-time staff members, reflecting its early-stage development status. The company was incorporated in Delaware in 2016 and is listed on Nasdaq, though it operates with significantly limited scale typical of preclinical and early clinical-stage biotechnology firms.